Testing effectiveness (Phase 2)Active Not RecruitingNCT02657551
What this trial is testing
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Who this might be right for
Thyroid Cancer
Dana-Farber Cancer Institute 8